Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1
Kenneth M. Comess(Abbott (United States)), David J. Burns, Russell A. Judge(AbbVie (United States)), Hua Tang(Guangdong University of Technology), Jonathan D. Trumbull, Tom Sowin(Abbott Fund), Mark E. Schurdak, Lan Gao(Zhengzhou University), Xueheng Cheng, Michael Coen, Haiying Zhang(Abbott Fund), Chang Park(Abbott Fund), Martin J. Voorbach(AbbVie (United States)), Zehan Chen(Xi'an University of Technology), Peter Kovar(AbbVie (United States))
Cited by 35
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents
|Journal of Biological Chemistry|2003|382
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
|ACS Medicinal Chemistry Letters|2014|331